Comparative Pharmacology
Head-to-head clinical analysis: KELNOR 1 50 versus SYEDA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KELNOR 1 50 versus SYEDA.
KELNOR 1/50 vs SYEDA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination hormonal contraceptive: ethinyl estradiol provides estrogenic activity, suppressing gonadotropin release; norethindrone acetate provides progestational activity, inhibiting ovulation and causing cervical mucus thickening.
Syeda is a combination of drospirenone and ethinyl estradiol, a contraceptive that suppresses gonadotropins, primarily inhibiting ovulation; drospirenone has antimineralocorticoid and antiandrogenic activity.
One tablet (norethindrone 1 mg/ethinyl estradiol 50 mcg) orally once daily, taken at the same time each day for 21 days, followed by 7 days of placebo.
1 tablet (3 mg drospirenone / 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo tablets.
None Documented
None Documented
Ethinyl estradiol: biphasic, terminal half-life 13-27 hours (mean ~17 h); norethindrone: monoexponential, half-life 5-14 hours (mean ~8 h). Steady-state achieved after 3-5 days. Accumulation may occur in patients with hepatic impairment.
Terminal elimination half-life of 12-15 hours; allows twice-daily dosing for sustained therapeutic levels.
Renal: ~50% (as metabolites, primarily ethinyl estradiol glucuronide and sulfate conjugates; norethindrone metabolites). Fecal: ~35% (biliary excretion of conjugates followed by hydrolysis and elimination). Unchanged drug: <5%.
Urinary excretion (40-60% as unchanged drug and metabolites); biliary/fecal elimination accounts for 15-25%.
Category C
Category C
Oral Contraceptive
Oral Contraceptive